Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-6-25
pubmed:abstractText
The treatment of traumatic brain injury (TBI) remains limited, and aside from surgical hematoma evacuation, clinical management is largely supportive and directed toward management of cerebral edema and intracranial hypertension. Secondary neuronal injury caused by ischemia and the development of cerebral edema may occur in the subacute phase, with intracranial pressures often peaking in the first several days following injury. Because inflammation contributes significantly to the pathophysiology of cerebral ischemia and endothelial dysfunction underlies the development of cerebral edema, therapeutic strategies that target the post-traumatic inflammatory cascade and reduce endothelial dysfunction hold enormous potential to improve clinical outcomes after TBI. Statins inhibit inflammation by suppressing inflammatory cytokine release, and by interfering with multiple steps of leukocyte recruitment and migration into the CNS. In this study, we demonstrate that treatment with atorvastatin and simvastatin markedly reduced functional neurological deficits after traumatic brain injury in mice. These effects were accompanied by histological reduction in degenerating hippocampal neurons and suppression of inflammatory cytokine mRNA expression in brain parenchyma. Furthermore, statin treatment improved cerebral hemodynamics following head injury. Thus, the administration of statins may represent a viable therapeutic strategy in the acute treatment of closed head injury.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0014-4886
pubmed:author
pubmed:issnType
Print
pubmed:volume
206
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
59-69
pubmed:meshHeading
pubmed-meshheading:17521631-Animals, pubmed-meshheading:17521631-Anti-Inflammatory Agents, pubmed-meshheading:17521631-Brain Edema, pubmed-meshheading:17521631-Brain Injuries, pubmed-meshheading:17521631-Brain Ischemia, pubmed-meshheading:17521631-Cerebrovascular Circulation, pubmed-meshheading:17521631-Chemotaxis, Leukocyte, pubmed-meshheading:17521631-Cognition Disorders, pubmed-meshheading:17521631-Cytokines, pubmed-meshheading:17521631-Disease Models, Animal, pubmed-meshheading:17521631-Encephalitis, pubmed-meshheading:17521631-Endothelial Cells, pubmed-meshheading:17521631-Heptanoic Acids, pubmed-meshheading:17521631-Hippocampus, pubmed-meshheading:17521631-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:17521631-Male, pubmed-meshheading:17521631-Mice, pubmed-meshheading:17521631-Mice, Inbred C57BL, pubmed-meshheading:17521631-Nerve Degeneration, pubmed-meshheading:17521631-Neurons, pubmed-meshheading:17521631-Pyrroles, pubmed-meshheading:17521631-RNA, Messenger, pubmed-meshheading:17521631-Recovery of Function, pubmed-meshheading:17521631-Simvastatin, pubmed-meshheading:17521631-Treatment Outcome
pubmed:year
2007
pubmed:articleTitle
Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury.
pubmed:affiliation
Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC 27710, USA.
pubmed:publicationType
Journal Article